Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis to Present at the UBS Virtual Healthcare Conference
11:00am, Monday, 11'th May 2020
REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.
H.C. Wainwright Sticks to Their Buy Rating for Codexis
10:51am, Monday, 11'th May 2020
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of
Codexis to Present at the UBS Virtual Healthcare Conference
12:00am, Monday, 11'th May 2020Codexis(CDXS) Q1 2020 Earnings Call Transcript
05:30am, Saturday, 09'th May 2020
Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codex
Edited Transcript of CDXS earnings conference call or presentation 7-May-20 8:30pm GMT
06:13pm, Friday, 08'th May 2020
Q1 2020 Codexis Inc Earnings Call
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Codexis Q1 EPS $(0.090) Beats $(0.140) Estimate, Sales $14.700M Beat $13.250M Estimate
08:46pm, Thursday, 07'th May 2020Codexis Reports First Quarter 2020 Financial Results
08:05pm, Thursday, 07'th May 2020
R&D; revenue increased 26% to $9.6 million fueled by the Novartis and Takeda strategic collaborations Withdraws 2020 financial guidance due to uncertainty of COVID-19.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
Codexis Reports Achieved Wave 2 Milestone Associated With CodeEvolver Platform, License Deal With Novartis
08:27pm, Wednesday, 06'th May 2020Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader
08:05pm, Wednesday, 06'th May 2020
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver® platform technology transfe
Codexis Expands and Strengthens its Leadership Team with Two Executive Hires
11:00am, Tuesday, 05'th May 2020
Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Codexis (NASDAQ:CDXS) Downgraded to "Buy" at ValuEngine
05:42am, Saturday, 02'nd May 2020
Codexis (NASDAQ:CDXS) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Friday, ValuEngine reports. A number of other eq
Codexis to Hold First Quarter 2020 Conference Call on May 7
11:00am, Thursday, 30'th Apr 2020
REDWOOD CITY, Calif., April 30, 2020 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2020 financial results.
